AnaptysBio (ANAB) is Initiated by Credit Suisse to “Outperform”

AnaptysBio (ANAB) was Initiated by Credit Suisse to “Outperform” and the brokerage firm has set the Price Target at $34. Credit Suisse advised their Clients and Investors in a research report released on Feb 21, 2017.

AnaptysBio

Add Comment